Elutia Inc. (ELUT) stock
Close on Nov 12, 2026Market cap $38.92MP/E –Yield –
Elutia Inc. grew revenue 79.4% to $16.96M over the twelve months to Sep 30, 2026. Free cash flow was -$50.68M. At the latest close the market valued the company at $38.92M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $38.92M
- P/E ratio
- –
- Price to sales
- 2.29
- Price to book
- 2.54
- Dividend yield
- –
- Free cash flow yield
- -130.21%
Fundamentals
- Revenue
- $16.96M
- Net income
- $54.39M
- EPS, diluted
- $0.87
- Free cash flow
- -$50.68M
- Book value per share
- $0.32
- Diluted shares
- 48M
Trading
- Next earnings
- Mar 10, 2027 (estimated, during market hours)
- Previous close
- $0.92
- Open
- $0.92
- Day's range
- $0.86 – $0.94
- Volume
- 83,188
- Average volume (20 days)
- 78,926
- Beta (5 years)
- 0.26
- 52-week range
- $0.50 – $1.39
- RSI (14 days)
- 55.8
- Volatility (1 year)
- 76.8%
- Relative volume
- 0.54×
- WACC
- 7.0%
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | ELUT | S&P 500 | Difference | ELUT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +11.7% | -2.7% | +14.4 pts | ||
| 3 months | +7.4% | -1.7% | +9.2 pts | ||
| Year to date | +26.9% | +11.9% | +15.0 pts | ||
| 1 year | +18.7% | +12.0% | +6.7 pts | ||
| 3 years | -40.2% | +78.2% | −118.4 pts | -15.8% | +21.2% |
| 5 years | -85.9% | +73.2% | −159.2 pts | -32.5% | +11.6% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Elutia filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Results
- Update
- Results
About Elutia
Biological Products, (No Diagnostic Substances)
Elutia Inc. develops and commercializes proprietary biologic matrix and drug-eluting biomatrix products designed for surgical reconstruction, soft tissue repair, and cardiovascular applications. Operating through reporting segments including Women’s Health and Cardiovascular, the company provides products such as SimpliDerm, a human acellular dermal matrix for soft tissue repair, and cardiovascular matrices including ProxiCor, Tyke, and VasCure. Its customer base consists of healthcare facilities and hospitals, supplied via independent sales agents, alongside plastic, reconstructive, cardiovascular, and general surgeons who utilize these products to support tissue healing and reduce post-operative complications.
Company profile, executives and historyElutia stock: common questions
What is Elutia's stock price?
ELUT closed at $0.88 on Nov 12, 2026, down 4.48% on the day. Over the past 52 weeks it traded between $0.50 and $1.39.
What is Elutia's market cap?
Elutia was worth $38.92M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
How much revenue does Elutia make?
Elutia reported revenue of $16.96M for the twelve months to Sep 30, 2026, up 79.4% from a year earlier.
Does Elutia pay a dividend?
No. Elutia has not paid a cash dividend over the last twelve months.
When does Elutia report earnings next?
Elutia is expected to report Q4 FY2026 results on Mar 10, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has ELUT stock performed over the past year?
Including dividends, ELUT returned +18.7% over the past year, against +12.0% for the S&P 500.
How many ELUT shares are sold short?
0M shares were sold short at the latest FINRA report, 0.16% of the float, or 1.0 days of average trading volume.
Who are Elutia's competitors?
Companies most similar to Elutia by business, industry and size include ZEOX, LCTX, LENZ, CELU, SCLX.
See a number that looks wrong?